Literature DB >> 2846341

Specific Epstein-Barr virus serological response in patients with nasopharyngeal carcinoma detected by immunoblotting.

R Cevenini1, M Donati, A Moroni, U Caliceti, A Rinaldi-Ceroni, M La Placa.   

Abstract

The specific humoral immune response against Epstein-Barr virus (EBV) antigens in patients with nasopharyngeal carcinoma (NPC) was compared to that of patients with infectious mononucleosis (IM) and other EBV-seropositive subjects using immunoblotting technique. Almost all sera from EBV serologically associated NPC reacted reproducibly with a major group of polypeptides (four to six) of early antigen (EA) complex with molecular weights ranging from 50 kD to 58 kD, and with some additional polypeptides. Sera from IM-patients reproducibly recognized only one polypeptide of 50 kD belonging to the major group of polypeptides of EA-complex. Sera from patients with other types of head and neck cancer and relatively high levels of IgG antibody against viral capsid antigen (VCA) and EA did not react reproducibly with any of the EBV-associated proteins.

Entities:  

Mesh:

Year:  1988        PMID: 2846341     DOI: 10.1007/bf00148913

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  22 in total

1.  Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells.

Authors:  L J Old; E A Boyse; H F Oettgen; E D Harven; G Geering; B Williamson; P Clifford
Journal:  Proc Natl Acad Sci U S A       Date:  1966-12       Impact factor: 11.205

2.  Qualitative and quantitative analyses of Epstein-Barr virus early antigen diffuse component by western blotting enzyme-linked immunosorbent assay with a monoclonal antibody.

Authors:  J C Lin; E I Choi; J S Pagano
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

3.  Epstein-Barr virus nuclear antigen (EBNA): size polymorphism of EBNA 1.

Authors:  M J Allday; A J MacGillivray
Journal:  J Gen Virol       Date:  1985-07       Impact factor: 3.891

4.  Evaluation of antibodies to Epstein-Barr virus in Italian patients with nasopharyngeal carcinoma.

Authors:  R Cevenini; M Donati; U Caliceti; A Moroni; I Tamba; F Rumpianesi
Journal:  J Infect       Date:  1986-03       Impact factor: 6.072

5.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  An immunoperoxidase assay for the detection of specific IgA antibody in Epstein-Barr virus infections.

Authors:  R Cevenini; M Donati; F Rumpianesi; A Moroni; P Paolucci
Journal:  J Clin Pathol       Date:  1984-04       Impact factor: 3.411

8.  Detection of virus-specific antigens in EB-(P3HR1) virus-superinfected Raji cells by immunoprecipitation.

Authors:  W W Bodemer; W C Summers; J C Niederman
Journal:  Virology       Date:  1980-06       Impact factor: 3.616

9.  Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.

Authors:  T Hadar; M Rahima; E Kahan; J Sidi; E Rakowsky; B Sarov; I Sarov
Journal:  J Med Virol       Date:  1986-12       Impact factor: 2.327

10.  Purification of a polypeptide complex (p52) belonging to the D-subspecificites of Epstein-Barr virus-induced early antigens.

Authors:  G Dölken; T Hecht; U Weitzmann; M Wagner; G W Löhr; F W Hirsch
Journal:  Virology       Date:  1986-01-15       Impact factor: 3.616

View more
  1 in total

1.  Circulating and tumor-infiltrating Foxp3⁺ regulatory T cell subset in Chinese patients with extranodal NK/T cell lymphoma.

Authors:  Rou-Jun Peng; Zhou-Feng Huang; Yi-Lan Zhang; Zhong-Yu Yuan; Yi Xia; Wen-Qi Jiang; Yi-Xin Zeng; Jiang Li
Journal:  Int J Biol Sci       Date:  2011-08-19       Impact factor: 6.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.